PharmaShots | Incisive News in 3 Shots

Subscribe Now

checkpoint therapeutics

Checkpoint Therapeutics’ Unloxcyt (Cosibelimab-ipdl) Receives the US FDA’s Approval for Cutaneous Squamous Cell Carcinoma (cSCC)

Checkpoint Therapeutics’ Unloxcyt (Cosibelimab-ipdl) Receives the US FDA’s Approval for Cutaneous Squamous Cell Carcinoma (cSCC)

December 13, 2024

Checkpoint Therapeutics Reports New Results from Pivotal Studies of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics Reports New Results from Pivotal Studies of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma

July 28, 2023

Checkpoint Therapeutics Reports Interim Results of Cosibelimab in Registration-Enabling Trial for Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics Reports Interim Results of Cosibelimab in Registration-Enabling Trial for Locally Advanced Cutaneous Squam...

June 17, 2022

Checkpoint Reports Results of Cosibelimab in Registration-Enabling Trial for Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Reports Results of Cosibelimab in Registration-Enabling Trial for Metastatic Cutaneous Squamous Cell Carcinoma

January 27, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us